Study of GV20-0251 for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have an advanced solid tumor that has continued to grow despite standard treatments.
- Your tumor must be measurable on imaging scans.
- You must be willing to have a fresh biopsy of your tumor before and during treatment (for part of the study).
- You cannot have active autoimmune disease, serious heart problems, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
This trial tests a new drug called GB268, which is designed to help your immune system fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This trial tests a new drug called GV20-0251 combined with an immunotherapy (anti-PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.